WebFilings | EDGAR view
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
Washington, DC 20549
_____________________________________________________________________
 
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 
______________________________________________________________________
 
Date of Report (Date of earliest event reported): January 19, 2011
 
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in charter)
 
DELAWARE
1-11083
04-2695240
(State or other
(Commission
(IRS employer
jurisdiction of
file number)
identification no.)
incorporation)
 
 
 
One Boston Scientific Place, Natick, Massachusetts
01760-1537
(Address of principal executive offices)
(Zip code)
 
Registrant's telephone number, including area code:   (508) 650-8000
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
 

ITEM 8.01.     OTHER EVENTS.
 
Boston Scientific Corporation (the Company) today announced the signing of a definitive merger agreement, under which the Company will acquire Atritech, Inc., a privately held company based in Plymouth, Minnesota. Atritech has developed a novel device designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke. Closing of the transaction is subject to customary conditions and is expected to be completed in the first quarter of 2011.
 
A copy of the Company's press release announcing the signing of the definitive agreement is included as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
 
 
ITEM 9.01. 
FINANCIAL STATEMENTS AND EXHIBITS.
 
 
(d) Exhibits
 
 
 
Exhibit  No.
Description
 
 
99.1 
Press Release issued by Boston Scientific Corporation dated January 19, 2011.
 
 
 
 
 

 
 

 
SIGNATURE
 
 
Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
                        
                                
Date: January 19, 2011
BOSTON SCIENTIFIC CORPORATION
 
 
 
 
 
 
By:
/s/ Vance R. Brown
 
 
 
Vance R. Brown
 
 
 
Vice President and Chief Corporate Counsel
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 

INDEX TO EXHIBITS
 
Exhibit  No.
Description
 
 
99.1 
Press Release issued by Boston Scientific Corporation dated January 19, 2011.